Estrella Immunopharma Stock Price, News & Analysis
UPTDU
NASDAQ
Company Description
Estrella Immunopharma, Inc., formerly known as TradeUP Acquisition Corp. (UPTD), successfully completed a business combination with Estrella Biopharma, Inc., focusing on T-cell therapies for blood cancers and solid tumors. Led by Dr. Cheng Liu, the company will operate under the name Estrella Immunopharma, Inc. The company's main product candidate, EB103, targets CD19 for B-cell leukemias and lymphomas, while EB104 targets CD19 and CD22 for B-cell malignancies. Estrella is also collaborating with Imugene Limited for oncolytic virus research.
Stock Performance
$—
0.00%
0.00
Last updated:
- %
Performance 1 year
$0.0
Market Cap
4.0M
Shares outstanding
Latest News
SEC Filings
No SEC filings available for Estrella Immunopharma.
Financial Highlights
—
Revenue (TTM)
—
Net Income (TTM)
—
Diluted EPS (TTM)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin
Upcoming Events
Frequently Asked Questions
What is the main focus of Estrella Immunopharma, Inc.?
Estrella is a preclinical-stage biopharmaceutical company developing ARTEMIS T-cell therapies targeting CD19 and CD22 to address treatment challenges for patients with blood cancers and solid tumors.
Who leads Estrella Immunopharma, Inc.?
Dr. Cheng Liu is the Founder and CEO of Estrella Immunopharma, Inc.
What are the lead product candidates of Estrella Immunopharma, Inc.?
EB103 targets CD19 for B-cell leukemias and lymphomas, while EB104 targets CD19 and CD22 for B-cell malignancies.
What collaboration does Estrella have with Imugene Limited?
Estrella is collaborating with Imugene Limited for oncolytic virus research to treat solid tumors using a 'mark and kill' strategy.
What was the recent business combination involving Estrella?
Estrella Immunopharma, Inc., formerly known as TradeUP Acquisition Corp. (UPTD), completed a successful business combination with Estrella Biopharma, Inc., to develop T-cell therapies for blood cancers and solid tumors.
What is the mission of Estrella Immunopharma, Inc.?
Estrella aims to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.
What were the key financing activities related to the business combination?
Estrella closed Series A preferred stock financings with gross proceeds of $9.75 million and a short-term debt financing with gross proceeds of $0.30 million. Additionally, UPTD closed a private placement with gross proceeds of $10.00 million.
What is Dr. Cheng Liu's statement regarding the transaction?
Dr. Liu, President and CEO of Estrella, expressed commitment to advancing clinical programs, particularly the anti-CD19 ARTEMIS T-cell therapy.
What are the new trading symbols for the combined company post-merger?
The combined company will trade on NASDAQ under the symbols 'ESLA' for common stock and 'ESLAW' for warrants.
Which legal firms served as advisors for the business combination?
US Tiger Securities, Inc. served as the financial advisor to UPTD, while Robinson & Cole LLP and Winston & Strawn LLP acted as legal advisors to UPTD and Estrella, respectively.
What is the background of TradeUP Acquisition Corp.?
TradeUP Acquisition Corp. was a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, or similar business combination.
What is Estrella Immunopharma working on developing?
Estrella Immunopharma is developing ARTEMIS T-cell therapies that target CD19 and CD22 to address treatment challenges for blood cancers and solid tumors.
Who is leading Estrella Immunopharma?
Dr. Cheng Liu is the Founder and CEO of Estrella Immunopharma.
What are the lead product candidates of Estrella Immunopharma?
The lead product candidates are EB103, targeting CD19, and EB104, targeting CD19 and CD22 for B-cell malignancies.
What collaboration is Estrella part of with Imugene Limited?
Estrella is collaborating with Imugene Limited for oncolytic virus research using EB103 to treat solid tumors.
What recent transaction did Estrella complete?
Estrella successfully completed a business combination with Estrella Biopharma, focusing on T-cell therapies for blood cancers and solid tumors.
What is the main mission of Estrella Immunopharma?
Estrella's mission is to harness the human immune system's evolutionary power to benefit cancer patients.
What funding activities were associated with the business combination?
Estrella completed Series A preferred stock financings and short-term debt financing, while UPTD finalized a private placement.
What are the trading symbols for the combined company post-merger?
The combined company will trade under the symbols 'ESLA' for common stock and 'ESLAW' for warrants on NASDAQ.
Which firms provided advisory services for the business combination?
US Tiger Securities, Inc. served as the financial advisor to UPTD, with legal advice from Robinson & Cole LLP and Winston & Strawn LLP.
What was TradeUP Acquisition Corp. primarily formed for?
TradeUP Acquisition Corp. was formed as a blank check company to pursue various business combinations and acquisitions.